Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Novartis Pluvicto prostate cancer radiotherapy. Novartis got a clinical data boost that could support its radiotherapy Pluvicto’s $2 billion-plus peak sales ambition.

- Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists ...

EAST HANOVER, N.J., March 23, 2022 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly ...

New report finds colorectal cancer rising among U.S. adults under 55 04:17. Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported ...

Novartis is investigating Pluvicto in earlier stages of disease, including metastatic hormone-sensitive prostate cancer (PSMAddition, NCT04720157) and oligometastatic prostate cancer (PSMA-DC ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...

Pluvicto, a drug to treat metastatic castration-resistant prostate cancer, also known as mCRPC, is in such short supply that its maker, Novartis, said it cannot allow further supply to new ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) – formerly known as 177Lu-PSMA-617 – has been cleared in the US for previously-treated patients with PSMA-positive metastatic castration ...

The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer, according ...

--Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, today announced preclinical results with ATNM-400 in prostate cancer models presented at the American ...